A. Alomran

Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial.

A. Gottlieb, A. Saraiya, S. Au, 2020, Journal of the American Academy of Dermatology.

Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa

A. Gottlieb, A. Saraiya, D. Rosmarin, 2019, The British journal of dermatology.

Apremilast in Combination With an Interleukin 17A Inhibitor in the Treatment of Recalcitrant Palmoplantar Psoriasis

A. Gottlieb, D. Rosmarin, M. Her, 2018, Journal of Psoriasis and Psoriatic Arthritis.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32‐week open‐label extension study with optional narrow‐band ultraviolet B

D. Rosmarin, P. Zancanaro, D. Joshipura, 2018, Journal of the American Academy of Dermatology.

Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions

A. Gottlieb, D. Rosmarin, P. Zancanaro, 2019, The Journal of dermatological treatment.